AstraZeneca: Selumetinib Designated as Breakthrough Therapy
April 01 2019 - 1:40AM
Dow Jones News
By Adam Clark
AstraZeneca PLC (AZN.LN) said Monday that its Selumetinib drug
has been granted a breakthrough therapy designation in the U.S. for
neurofibromatosis type 1, a genetic condition which causes tumors
to grow in the nervous system.
The drug company said the designation is for treatment of
pediatric patients aged three years and older, and means
Selumetinib could get an expedited regulatory review.
The designation is based on a phase 2 trial for Selumetinib. The
drug is being jointly developed by AstraZeneca and Merck & Co.
Inc. (MRK).
Write to Adam Clark at adam.clark@dowjones.com;
@AdamDowJones
(END) Dow Jones Newswires
April 01, 2019 02:25 ET (06:25 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From May 2023 to May 2024